🔗 Share this article

Elected officials have issued warnings that the United Kingdom's recent agreements with Washington are "lacking a solid foundation." This follows revelations that a much-touted deal on medicines, which commits to zero tariffs in exchange for the NHS facing higher prices, lacks any formal legal text beyond vague headline terms published in government press releases.

A Deal Without Detail

The US-UK pharmaceuticals agreement, hailed as a "generational" achievement, is still an "broad understanding" without a signed legal text. It has been highlighted that the official announcements from the UK and US governments frame the deal in divergent terms. The British version focuses on securing "duty-free access" as a unique achievement, while the American announcement dwells on the expectation for the NHS to pay 25% more for new medications.

"We face a genuine possibility that the UK government has made commitments to increase medicine costs in return for nothing more than a assurance from President Trump," stated David Henig, a trade expert. "History shows he has a tendency for not keeping promises."

Wider Concerns Amidst a Suspended Agreement

Worries have been intensified by Washington's move to put on ice the high-value digital accord, which was previously heralded as "a huge leap forward" in the bilateral relationship. The US pointed to a failure to advance from the UK on lowering trade barriers as the reason for the pause.

In a separate development, concessions secured for British farmers as part of an initial accord have yet to be formally ratified by the US, despite a looming January deadline. "We have been informed that that the US has not finalized the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

Privately, ministers have voiced worries that the government's agreements with the US are lacking substance. One minister was quoted as stating the series of agreements as "resting on shaky ground," while another described the situation as the "current reality" in the transatlantic relationship, marked by "increased uncertainty and instability."

Layla Moran, chair of the health select committee, argued: "What is even more astonishing than the administration's tactics is the UK government's optimistic assumption that his administration is a good faith actor. The NHS is not a bargaining chip."

A Mixed Picture of Success and Setback

Ministry sources have sought to reduce the possibility of the US withdrawing from the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been advocating for the agreement, desiring stability on imports and pricing, making it less abstract than the paused tech deal.

Officials admit that volatility is inherent in dealing with the Trump administration. However, they maintain that the UK has obtained tangible results for businesses, such as lower steel tariffs compared to other nations. "Our achievement of 25% steel tariffs, which is better than the rate for the rest of the world, is not flimsy," one official said.

However, delays have arisen in enacting the initial US-UK accord. Promised reciprocal agricultural allowances have failed to be approved, and the pledge to "eliminate duties on UK metals" has remains unmet, with tariffs staying at 25%.

As negotiations continue, the two sides have agreed to resume talks on the suspended digital agreement in January, following what were described as "very positive" meetings between UK and US officials in Washington.